OUTLOOK THERAPEUTICS INC
$ 0.37
19.66%
20 Apr - close price
- Market Cap 32,346,700 USD
- Current Price $ 0.37
- High / Low $ 0.39 / 0.33
- Stock P/E N/A
- Book Value -0.60
- EPS -2.89
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -2.09 %
- ROE -0.04 %
- 52 Week High 3.39
- 52 Week Low 0.16
About
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.
Analyst Target Price
$4.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-12-19 | 2025-08-14 | 2025-05-14 | 2025-02-12 | 2024-12-20 | 2024-08-14 | 2024-05-15 | 2024-02-14 | 2023-12-22 | 2023-08-14 | 2023-05-15 |
| Reported EPS | -0.22 | -0.28 | -0.55 | -0.3365 | -0.89 | -0.9369 | -0.83 | -1.55 | -0.04 | -0.05 | -0.08 | -0.03 |
| Estimated EPS | -0.1733 | -0.06 | -0.06 | -0.5533 | -0.52 | -0.9 | -1.01 | -0.85 | -0.05 | -0.06 | -0.05 | -0.06 |
| Surprise | -0.0467 | -0.22 | -0.49 | 0.2168 | -0.37 | -0.0369 | 0.18 | -0.7 | 0.01 | 0.01 | -0.03 | 0.03 |
| Surprise Percentage | -26.9475% | -366.6667% | -816.6667% | 39.1831% | -71.1538% | -4.1% | 17.8218% | -82.3529% | 20% | 16.6667% | -60% | 50% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OTLK
2026-04-08 11:40:37
H.C. Wainwright has reiterated its Hold rating for Outlook Therapeutics (OTLK.US) and maintained a target price of $0.5. This signifies the firm's continued neutral stance on the company's stock at the current valuation.
2026-04-08 07:09:48
Outlook Therapeutics has filed a formal dispute resolution request with the FDA after its vision loss drug, ONS-5010/LYTENAVA, received a Complete Response Letter in December 2025. The FDA accepted the request, and a meeting with the deciding official is scheduled for April 2026. The company maintains that clinical data supports the drug's efficacy, which has already been approved in Europe, and challenges the FDA's claim of a lack of substantial effectiveness evidence.
2026-04-08 07:09:48
Outlook Therapeutics announced that the FDA has accepted its formal dispute resolution request (FDRR) regarding the Complete Response Letter for ONS-5010/LYTENAVA™ (bevacizumab-vikg), a treatment for neovascular age-related macular degeneration. The company believes its clinical data from the NORSE TWO and NORSE EIGHT trials provide sufficient evidence for approval and looks forward to a meeting with the FDA in April 2026. If approved, ONS-5010/LYTENAVA™ would be the first FDA-approved ophthalmic formulation of bevacizumab with standardized manufacturing and robust pharmacovigilance.
2026-04-08 06:40:05
Outlook Therapeutics announced that its formal dispute resolution request (FDRR) to the FDA for ONS-5010/LYTENAVA™ has been accepted. This request follows a Complete Response Letter for their BLA for the treatment of neovascular age-related macular degeneration. A meeting with the deciding official is scheduled for April 2026.
2026-04-08 05:40:41
Outlook Therapeutics announced it has submitted and had accepted a formal dispute resolution request (FDRR) with the FDA regarding its Complete Response Letter for ONS-5010/LYTENAVA™ for treating neovascular age-related macular degeneration. The company believes its clinical data from NORSE TWO and NORSE EIGHT trials sufficiently demonstrate the safety and efficacy of ONS-5010. A meeting with the deciding official is scheduled for April 2026, as Outlook Therapeutics continues to seek FDA approval for what would be the first ophthalmic formulation of bevacizumab.
2026-04-08 05:09:33
Outlook Therapeutics Inc. has announced that the FDA accepted its Formal Dispute Resolution Request (FDRR) regarding the Complete Response Letter for ONS-5010/LYTENAVA for neovascular age-related macular degeneration. The FDA has granted a meeting with the deciding official in April 2026. The company believes its presented data supports the efficacy and safety of ONS-5010, which previously met primary and secondary endpoints in a Phase 3 trial.
